The adverse events of influenza A (H1N1) vaccination and its risk factors in healthcare personnel in 18 military healthcare units in Korea.

In this study, we characterized adverse events related to influenza A (H1N1) vaccination and studied the factors that influence the occurrence of these events. A total of 4,302 personnel in 18 military healthcare units in Korea received 0.5 ml of inactivated H1N1 vaccine. The study questionnaires were answered by 3,939 (91.6%) personnel, at both 2 weeks and 4 weeks after vaccination. Among these subjects, 3,531 (82.1%) who responded to all questions in the questionnaire were studied. After immunization, military doctors were ordered to report the occurrence of any adverse event related to the vaccine for 2 months. According to the responses of the subjects, the most prevalent events were fatigue (11.3%), pain at the injection site (8.38%), and myalgia (6.97%). Female gender, being in the age range of 20-49 years, obesity, regular alcohol consumption, and comorbidity, but not smoking status or pregnancy, were related to a high incidence of local or systemic adverse events after H1N1 vaccination. A total of 14 cases of adverse events were reported by the military doctors. In most reported cases, the subjects had fever in addition to the primary adverse event, and one patient was diagnosed with pneumonia. In conclusion, the overall burden of adverse events related to influenza A (H1N1) vaccination was not inconsequential, but most symptoms were mild. Female gender, middle-age range of 20-49 years, obesity, regular alcohol consumption, and comorbidity were risk factors for the occurrence of adverse events after H1N1 vaccination.

[1]  J. Tokars,et al.  H1N1 vaccine safety monitoring: beyond background rates , 2010, The Lancet.

[2]  J. Devaster,et al.  Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.

[3]  A. Caplan.  Unlicensed pandemic influenza A H1N1 vaccines , 2010, The Lancet.

[4]  A. Arguedas,et al.  Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. , 2010, The New England journal of medicine.

[5]  Ruihua Yin,et al.  Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. , 2010, American journal of epidemiology.

[6]  J. McVernon,et al.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. , 2010, JAMA.

[7]  D. Wood,et al.  Defining the safety profile of pandemic influenza vaccines , 2010, The Lancet.

[8]  Z. Vajo,et al.  Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial , 2010, The Lancet.

[9]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[10]  S. Black,et al.  Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines , 2009, The Lancet.

[11]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[12]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[13]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[14]  Z. Vajo,et al.  A Single-Dose Influenza A (H5N1) Vaccine Safe and Immunogenic in Adult and Elderly Patients: an Approach to Pandemic Vaccine Development , 2009, Journal of Virology.

[15]  T. Hampton.  H1N1 vaccine urged for health workers, but some resist getting on board. , 2009, JAMA.

[16]  T. Merlin,et al.  A primer on strategies for prevention and control of seasonal and pandemic influenza. , 2009, American journal of public health.

[17]  R. Jacobson,et al.  Requiring influenza vaccination for health care workers: seven truths we must accept. , 2005, Vaccine.

[18]  Karen McAulay,et al.  Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a randomised controlled trial , 2000, The Lancet.

[19]  M. Virtanen,et al.  Randomized, placebo-controlled double blind study on the efficacy of influenza immunization on absenteeism of health care workers. , 1999, The Pediatric infectious disease journal.

[20]  M. Steinhoff,et al.  Effectiveness of influenza vaccine in health care professionals: a randomized trial. , 1999, JAMA.

[21]  K. Nichol,et al.  Influenza Vaccination of Healthcare Workers , 1997, Infection Control & Hospital Epidemiology.

[22]  J. Stockman.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2011 .

[23]  Gina M. Conenello,et al.  First Season of 2009 H1N1 Influenza. , 2010, The Mount Sinai journal of medicine, New York.

[24]  Updated recommendations from the Advisory Committee on Immunization Practices in response to delays in supply of influenza vaccine for the 2000-01 season. , 2000, MMWR. Morbidity and mortality weekly report.

[25]  P. Smith,et al.  Use of the case-control approach in vaccine evaluation: efficacy and adverse effects. , 1999, Epidemiologic reviews.

[26]  R. Bennett.  Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of elderly patients , 1997 .